Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wojciech Michalak

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Plos One|January 8, 2019
Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysisMieszko Kozikowski, Wojciech Malewski, Wojciech Michalak, et al.
Molecular & Cellular Proteomics : MCP|August 27, 2019
ComplexBrowser: A Tool for Identification and Quantification of Protein Complexes in Large-scale Proteomics DatasetsWojciech Michalak, Vasileios Tsiamis, Veit Schwämmle, et al.
Journal of Medical Economics|June 28, 2025
Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)Wojciech Michalak, Zhenxiang Zhao, Mads Faurby, et al.
Contemporary Oncology (Poznan, Poland)|May 6, 2026
Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative reviewKrzysztof Michalak, Łukasz Mazur, Alicja Bujara, et al.
Clinical Therapeutics|August 14, 2025
Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)Wojciech Michalak, Zhenxiang Zhao, Mads Faurby, et al.
Alzheimer Disease and Associated Disorders|January 26, 2024
Rescreening on RBANS Delayed Memory Index? Forget About It!Marwan N Sabbagh, Wojciech Michalak, Charlotte Thim Hansen, et al.
Obesity Science & Practice|February 9, 2024
Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE)Aleksandrina Ruseva, Wojciech Michalak, Zhenxiang Zhao, et al.
Advances in Therapy|August 6, 2025
Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort StudyAleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, et al.
Current Medical Research and Opinion|December 6, 2025
Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)Aleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, et al.
Diabetes, Obesity & Metabolism|June 1, 2026
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment ComparisonWojciech Michalak, Martin Bøg, Theiss Bendixen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Plos One|January 8, 2019
Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysisMieszko Kozikowski, Wojciech Malewski, Wojciech Michalak, et al.
Molecular & Cellular Proteomics : MCP|August 27, 2019
ComplexBrowser: A Tool for Identification and Quantification of Protein Complexes in Large-scale Proteomics DatasetsWojciech Michalak, Vasileios Tsiamis, Veit Schwämmle, et al.
Journal of Medical Economics|June 28, 2025
Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)Wojciech Michalak, Zhenxiang Zhao, Mads Faurby, et al.
Contemporary Oncology (Poznan, Poland)|May 6, 2026
Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative reviewKrzysztof Michalak, Łukasz Mazur, Alicja Bujara, et al.
Clinical Therapeutics|August 14, 2025
Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)Wojciech Michalak, Zhenxiang Zhao, Mads Faurby, et al.
Alzheimer Disease and Associated Disorders|January 26, 2024
Rescreening on RBANS Delayed Memory Index? Forget About It!Marwan N Sabbagh, Wojciech Michalak, Charlotte Thim Hansen, et al.
Obesity Science & Practice|February 9, 2024
Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE)Aleksandrina Ruseva, Wojciech Michalak, Zhenxiang Zhao, et al.
Advances in Therapy|August 6, 2025
Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort StudyAleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, et al.
Current Medical Research and Opinion|December 6, 2025
Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)Aleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, et al.
Diabetes, Obesity & Metabolism|June 1, 2026
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment ComparisonWojciech Michalak, Martin Bøg, Theiss Bendixen, et al.
Pageof 3